Freenome Unveils SimpleScreen Lung and Combined Lung-Colorectal Cancer Blood Test in October 2026
Freenome revealed SimpleScreen Lung and a pioneering combined test enabling eligible patients to undergo screening for both lung and colorect ...
Model output · Signal date 2026-11-06
Freenome, Inc. (FRNM) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
-52.0%
Spearman, 39 dates
Market Cap
$1.09B
small-cap · #15 of 27 peers
Summary
Freenome, Inc. (FRNM) stock forecast summary
Our AI scores Freenome, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Freenome, Inc. is a small-cap company with a market capitalization of $1.09B. It ranks number 15 by market capitalization among the 27 Services-Medical Laboratories issuers in our coverage with a current forecast.
For FRNM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -52.0%, measured on 39 forecast dates between 2026-06-16 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 35.0%, measured on 82 forecast dates between 2026-06-16 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, FRNM included.
Price
FRNM price chart and AI forecast
Cross-section · 2026-11-06
How FRNM ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Freenome, Inc. (FRNM) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | FRNM | Rank |
|---|---|---|
| Market Cap | $1.09B | 15/27 |
Profitability & Margins
| Metric | FRNM | Rank |
|---|---|---|
| ROA | -1.9% | 5/18 |
| ROIC | -5.3% | 9/22 |
Financial Health
| Metric | FRNM | Rank |
|---|---|---|
| Current Ratio | 0.20x | 23/24 |
| Working Capital | -$3M | 21/24 |
Cash Flow
| Metric | FRNM | Rank |
|---|---|---|
| Operating Cash Flow | -$910K | 14/25 |
Income Statement
| Metric | FRNM | Rank |
|---|---|---|
| Operating Income | -$4M | 11/24 |
| Net Income | -$2M | 5/19 |
Dividend & Shareholder Information
| Metric | FRNM | Rank |
|---|---|---|
| Shares Outstanding | 107M | – |
| Net Income Growth | -168.5% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $740K | |
| Cash & Short-term Investments | $440K | |
| Total Liabilities | $7M |
Quarterly Financial Reports
FRNM quarterly financials and insider trading
Industry Peers · Services-Medical Laboratories
Freenome, Inc. (FRNM) industry peers
Companies classified under the same SEC industry code as Freenome, Inc. (Services-Medical Laboratories): 28 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| FRNM Freenome, Inc. | $1.09B | |
| NTRA Natera, Inc. | $44.78B | |
| LH Labcorp Holdings Inc. | $29.77B | |
| DGX Quest Diagnostics Inc | $28.12B | |
| GH Guardant Health, Inc. | $20.25B | |
| CAI Caris Life Sciences, Inc. | $7.13B | |
| RDNT Radnet, Inc. | $5.98B | |
| GRAL Grail, Inc. | $5.42B | |
| BLLN Billiontoone, Inc. | $5.38B | |
| CDNA Caredx, Inc. | $4.13B | |
| CELC Celcuity Inc. | $3.27B | |
| FTRE Fortrea Holdings Inc. | $2.12B | |
| VCYT Veracyte, Inc. | $1.94B | |
| PSNL Personalis, Inc. | $1.69B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.29B | |
| CSTL Castle Biosciences Inc | $993M | |
| FLGT Fulgent Genetics, Inc. | $653M | |
| XGN Exagen Inc. | $184M | |
| BNR Burning Rock Biotech Ltd | $143M | |
| BDSX Biodesix Inc | $90M | |
| SERA Sera Prognostics, Inc. | $82M | |
| MDXH Mdxhealth Sa | $14M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $4M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| FCHS First Choice Healthcare Solutions, Inc. | $150K | |
| RNLXY Renalytix Plc | N/A |
Where FRNM sits on the market map
Industrial Applications and Services · Services-Medical Laboratories
News
Freenome, Inc. (FRNM) stock news
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential ...
Perceptive Capital Solutions Corp and Freenome Announce Effectiveness of Registration Statement for Proposed Business Combination
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FAQ
Freenome, Inc. (FRNM) stock forecast FAQ
What is the Freenome, Inc. (FRNM) stock forecast?
Our AI scores Freenome, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Freenome, Inc. stock predictions?
For FRNM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -52.0%, measured on 39 forecast dates between 2026-06-16 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 35.0%, measured on 82 forecast dates between 2026-06-16 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Freenome, Inc. forecasts updated?
Freenome, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Freenome, Inc.'s industry peers?
28 issuers in our coverage, FRNM included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.